NVCR NASDAQ
Novocure Ltd
1W: -5.7%
1M: -16.2%
3M: -13.7%
YTD: +13.9%
1Y: +6.9%
3Y: -12.1%
5Y: -88.3%
$14.94
-0.98 (-6.16%)
Weekly Expected Move ±6.6%
$13
$14
$15
$16
$17
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
5 relationships5
As Filer
counterparties named
0
As Counterparty
mentioned by others
2
Rel. Types
2021-12-07
Earliest Filing
2022-05-26
Latest Filing
partner: 4
target: 1
Counterparties (Filed by NVCR)
5 relationshipsCompanies named in NVCR's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Merck International GmbH | MRK | partner | Partner in Clinical Trial Collaboration and Supply Agreement for Optune device study | 2022-05-26 | View |
| MSD International Business GmbH | — | partner | Partner in Clinical Trial Collaboration and Supply Agreement providing pembrolizumab | 2022-05-26 | View |
| Novocure Inc. | NVCR | partner | Indirect wholly-owned subsidiary of NovoCure Limited that signed the Purchase Agreement. | 2021-12-07 | View |
| 64 Vaughan Mall, LLC | — | target | Seller of the office building located at 64 Vaughan Mall in Portsmouth, New Hampshire. | 2021-12-07 | View |
| Hampshire Development Corporation | — | partner | Affiliate of the Seller entering into a construction agreement for the office building. | 2021-12-07 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-10-01 | Regulation FD; Exhibits | View | |
| 2026-09-09 | Officer/Director Change; Exhibits | View | |
| 2026-09-01 | Other Events; Exhibits | View | |
| 2026-07-23 | Earnings Release; Exhibits | View | |
| 2026-06-30 | Regulation FD; Exhibits | View | |
| 2026-06-18 | Regulation FD; Exhibits | View | |
| 2026-06-05 | Officer/Director Change; Shareholder Vote; Exhibits | View | |
| 2026-04-30 | Earnings Release; Exhibits | View | |
| 2026-04-24 | Officer/Director Change; Exhibits | View | |
| 2026-04-09 | Officer/Director Change; Exhibits | View | |
| 2026-03-26 | Regulation FD; Exhibits | View | |
| 2026-02-26 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-02-24 | Regulation FD Disclosure | View | |
| 2026-02-11 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2026-02-05 | Regulation FD Disclosure | View | |
| 2026-01-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-12-01 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View | |
| 2025-10-30 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-09-15 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-08-28 | Regulation FD Disclosure; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR